– SWEDEN, Stockholm – The Board of Directors has appointed Niels Christiansen as the new CEO of Bactiguard (STO:BACTIB). Niels Christiansen has extensive management experience from various positions in the medical device, life science and energy sectors, most recently as the CEO of HemoCue AB. He will assume his new position in Bactiguard on March 16. At that time, Johan Rugfelt will return to his previous position as Chief Operating Officer (COO).

The recruitment process was initiated in December, when Johan Rugfelt informed the Chairman of the Board that he wanted to resign from his position as CEO of Bactiguard. When Niels Christiansen assumes the role as CEO, Johan Rugfelt will return to his previous position as Chief Operating Officer in the company.

The Board’s search criteria for the new candidate have been strong leadership skills, a track record of developing businesses and generating growth, experience of acting in an international, listed environment and from the medical device or life science industry.

“I am very pleased that we have managed to attract Niels Christiansen to join Bactiguard. The company is in a development and growth phase and Niels has extensive experience of developing major business, like Siemens, as well as smaller growth enterprises, such as HemoCue. He has a strong track record of leading organizations in transition and generating growth in an international environment”, says Christian Kinch, Chairman of Bactiguard.

“Johan Rugfelt will return to his previous position as COO, as his private situation doesn’t allow him to continue as CEO. By doing so, we secure important continuity in the company”, Christian Kinch continues.

“Bactiguard’s technology saves lives, which is an important driving force for me. Hospital acquired infections and the spread of multi resistant bacteria are major challenges to society, which Bactiguard contributes to preventing. I am therefore proud over the possibility to lead the company in the expansion phase ahead of us”, says Niels Christiansen.

Niels Christiansen is 54 years old and was the CEO of HemoCue AB between 2008 and 2014. Prior to that, he was employed by Siemens AG for more than 20 years in various CEO functions and managerial positions in R&D, sales, marketing, strategy and business development, in the medical device and energy sectors of industry.

He has a Bachelor of Engineering from the Technical University of Denmark and a Master of Business Administration from Rutgers University, New Jersey.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 11 February 2015, at 08.00

About Bactiguard

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare-related infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare-associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013 and has 60 employees, headquarters in Stockholm and production facilities in Sweden and Malaysia. The Bactiguard share is listed on Nasdaq Stockholm.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.